Effectiveness of palonosetron for preventing delayed chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy in patients with gastrointestinal cancer

Supportive Care in Cancer

Volumn 22, Issue 4, 2014, Pages 905-909

  Murakami, Michiyasu ^a   Hashimoto, Hiroki ^a   Yamaguchi, Kyohei ^a   Yamaguchi, Ikuko ^a   Senba, Shozo ^a   Siraishi, Takeshi ^a  

^a MATSUYAMA RED CROSS HOSPITAL   (Japan)

Author keywords

Antiemesis; Gastrointestinal cancer; Moderately emetogenic chemotherapy; Palonosetron

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; DEXAMETHASONE; FLUOROURACIL; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; GRANISETRON; IRINOTECAN; LEVOLEUCOVORIN; OXALIPLATIN; PALONOSETRON;

ADULT; AGE; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CHEMOPROPHYLAXIS; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL EFFECTIVENESS; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; DISEASE CONTROL; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG USE; DRUG WITHDRAWAL; FEMALE; GENDER; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; QUESTIONNAIRE; RISK FACTOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIEMETICS; ANTINEOPLASTIC AGENTS; FEMALE; GASTROINTESTINAL NEOPLASMS; GRANISETRON; HUMANS; ISOQUINOLINES; MALE; MIDDLE AGED; NAUSEA; PROSPECTIVE STUDIES; QUESTIONNAIRES; QUINUCLIDINES; VOMITING;

EID: 84895895712     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-013-2046-6     Document Type: Article

References (22)

1. Goedhals L, Heron JF, Kleisbauer JP et al (1998) Control of delayed nausea and vomiting with granisetron plus dexamethasone or dexamethasone alone in patients receiving highly emetogenic chemotherapy: a double-blind, placebo-controlled, comparative study. Ann Oncol 9:661-666 (Pubitemid 28318201)
2. Latreille J, Pater J, Johnston D et al (1998) Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 16:1174-1178 (Pubitemid 28108755)
3. The Italian Group for Antiemetic Research (2000) Dexamethasone alone or in combination with ondansetron for prevention of delayed nausea and vomiting induced by chemotherapy. N Engl J Med 342:1554-1559
4. Geling O, Eichler HG (2005) Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 h after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol 23:1289-1294 (Pubitemid 46202287)
5. Wong EH, Clark R, Leung E et al (1995) The interaction of RS25259-197, a potent and antagonist, with 5-HT3 receptors, in vitro. Br J Pharmacol 114:851-859
6. Maemondo M, Masuda N, Sekine I et al (2009) A phase II study of palonosetron combined with dexamethasone to prevent nausea and vomiting induced by highly emetogenic chemotherapy. Ann Oncol 20:1860-1866
7. Rojas C, Stathis M, Thomas AG et al (2008) Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor. Anesth Analg 107:469-478
8. Rojas C, Thomas AG, Alt J et al (2010) Palonosetron triggers 5-HT(3) receptor internalization and causes prolonged inhibition of receptor function. Eur J Pharmacol 626:193-199
9. Saito M, Aogi K, Sekine I et al (2009) Palonosetron plus dexamethasone versus granisetoron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind double-dummy randomised comparative phase III trial. Lancet Oncol 10:115-124
10. Horie Y, Boku N (2012) A guideline for antimetics use for patients with malignancies. Gan To Kagaku Ryoho 39:1163-1168, Article in Japanese
11. Molassiotis A, Coventry PA, Stricker CT, Clements C, Eaby B, Velders L, Rittenberg C, Gralla RJ (2007) Validation and psychometric properties of a short clinical scale to measure chemotherapy-induced nausea and vomiting: the MASCC Antiemesis Tool (MAT). J Pain Symptom Manag 34:148-159 (Pubitemid 47096779)
12. Botrel TE, Clark OA, Clark L et al (2011) Efficacy of palonosetron compared to other serotonin inhibitors in preventing chemotherapy-induced nausea and vomiting in patients receiving moderately or highly emetogenic treatment: systematic review and meta-analysis. Support Care Cancer 19:823-832
13. Roila F, Herrstedt J, Apro M et al (2010) Guideline update for MASCC and ESMO in the prevention of chemotherapy and radiotherapy induced nausea and vomiting; results of the Perugia consensus conference. Ann Oncol 21(Suppl 5):232-243
14. Basch E, Prestrud AA, Hesketh PJ et al (2011) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 26:4189-4198
15. National Comprehensive Cancer Network: NCCN Clinical Practice Guideline in Oncology TM; Antiemesis Ver.1.2012
16. Sepulveda-Vidosola AC, Betanzos-Cabrera Y, Lastiri GG et al (2008) Palonosetron hydrochloride is an effective and safe option to prevent chemotherapy-induced nausea and vomiting in children. Arch Med Res 39:601-606 (Pubitemid 352033608)
17. Aapro MS, Grunberg SM, Manikhas GM et al (2006) A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 17:1441-1449 (Pubitemid 44400384)
18. Eisenberg P, Figueroa-Vadillo J, Zamora R et al (2003) Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer 98:2473-2482 (Pubitemid 37466663)
19. Gralla R, Lichinitser M, Van Der Vegt S et al (2003) Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of double-blind randomized phase III trial comparing single-dose of palonosetron with ondansetron. Ann Oncol 14:1570-1577 (Pubitemid 37304615)
20. Yu Z, Liu W, Wang L et al (2008) The efficacy and safety of palonosetron compared with granisetron in preventing highly emetogenic chemotherapy-induced vomiting in the Chinese cancer patients: a phase II, randomized, double-blind parallel, comparative clinical trial. Support Care Cancer 17:99-102
21. Navari RM (2003) Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting - two new agents. J Support Oncol 1:89-103
22. Sekine I, Segawa Y, Kubota K et al (2013) Risk factors of chemotherapy-induced nausea and vomiting: index for personalized antiemetic prophylaxis. Cancer Sci 104:711-717